ACR — Acrux Share Price
Last Trade - 00:00- AU$26.37m
- AU$17.23m
- AU$4.17m
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | |||
| EPS Growth (f) | |||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | |||
| Price to Tang. Book | |||
| Price to Free Cashflow | |||
| Price to Sales | |||
| EV to EBITDA | |||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | |||
| Return on Equity | |||
| Operating Margin | |||
Financial Summary
| Year End 30th Jun | Unit | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 28.56 | 23.93 | 3.43 | 5.29 | 3.94 | n/a | n/a | -30.99% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +16.62 | -48.39 | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Acrux Limited is a drug development company. The Company is engaged in developing and commercializing branded and generic transdermal and topical pharmaceuticals for global markets. The Company's transdermal or topical pharmaceutical product portfolio can be segregated into approximately two streams, such as generic pharmaceutical products and specialty pharmaceutical products. The Company's products include Axiron, Ellavie, Evamist and Lenzetto. Axiron (testosterone) topical solution CIII is a testosterone topical solution approved for application via an armpit (underarm) applicator. It has developed the estradiol spray for women, used to treat moderate to severe hot flushes commonly associated with menopause. In the United States, the Company's estradiol spray is branded Evamist. The Company has licensed its estradiol product to Gedeon Richter to commercialize in various territories, including Europe and Eurasia. Gedeon Richter has branded the estradiol spray as Lenzetto.
Directors
- Ross Dobinson NEC
- Michael Kotsanis
- Deborah Ambrosini
- Joanna Johnson
- Felicia Colagrande
- Charles O'Sullivan
- Don Brumley
- Geoffrey Brooke
- Timothy Oldham
- Last Annual
- June 30th, 2020
- Last Interim
- December 31st, 2020
- Incorporated
- March 19th, 1998
- Public Since
- September 29th, 2004
- No. of Shareholders
- 5,557
- No. of Employees
- 43
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 210,993,671
- Address
- 103-113 Stanley St, West Melbourne, MELBOURNE, 3003
- Web
- http://www.acrux.com.au/irm/content/default.aspx
- Phone
- +61 383790100
- Auditors
- Pitcher Partners
Latest News for ACR
Upcoming events for ACR
Full Year 2021 Acrux Ltd Earnings Release
Similar to ACR
CLARITY PHARMACEUTICALS ORD
Australian Stock Exchange - SEATS
NUTRITIONAL GROWTH SOLUTIONS ORD
Australian Stock Exchange - SEATS
FAQ
As of Today at 19:55 UTC, shares in Acrux are trading at AU$0.13. This share price information is delayed by 15 minutes.
Shares in Acrux last closed at AU$0.13 and the price had moved by -21.88% over the past 365 days. In terms of relative price strength the Acrux share price has underperformed the ASX All Ordinaries Index by -38.11% over the past year.
The overall consensus recommendation for Acrux is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Acrux does not currently pay a dividend.
Acrux does not currently pay a dividend.
Acrux does not currently pay a dividend.
To buy shares in Acrux you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of AU$0.13, shares in Acrux had a market capitalisation of AU$26.37m.
Here are the trading details for Acrux:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: ACR
Based on an overall assessment of its quality, value and momentum Acrux is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Acrux is AU$0.23. That is 85.6% above the last closing price of AU$0.13.
Analysts covering Acrux currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Acrux. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -34.89%.
As of the last closing price of AU$0.13, shares in Acrux were trading -20.27% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We are not able to find PE ratio data for Acrux.
Acrux's management team is headed by:
- Ross Dobinson - NEC
- Michael Kotsanis -
- Deborah Ambrosini -
- Joanna Johnson -
- Felicia Colagrande -
- Charles O'Sullivan -
- Don Brumley -
- Geoffrey Brooke -
- Timothy Oldham -
We do not have data on Acrux's shareholders